Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Neurology · Developmental and Epileptic Encephalopathy

Targeted Hope: Treatment and Precision Medicine

At a Glance

Treating Developmental and Epileptic Encephalopathy (DEE) now focuses on precision medicine, which targets the specific genetic mutation causing your child's seizures. Tailored approaches include specific medications, strict medical diets, and emerging gene therapies.

Treating Developmental and Epileptic Encephalopathy (DEE) has shifted from a “one-size-fits-all” approach to Precision Medicine. This means instead of just trying to “stop the seizures,” doctors now aim to treat the underlying genetic problem [1]. This strategy is designed to improve not only seizure control but also your child’s developmental outcome and quality of life [1][2].

Precision Therapies: Targeted for the Gene

A precision therapy is a medication chosen because it interacts directly with the protein affected by your child’s genetic mutation.

  • SCN1A (Dravet Syndrome): Because this is a “Loss-of-Function” condition, the goal is to boost the brain’s quieting signals [3].
    • Approved Precision Meds: Fenfluramine, Stiripentol, and Cannabidiol are recognized treatments that help reduce seizures in Dravet [4][5][6].
    • CRITICAL SAFETY: In Dravet Syndrome, standard sodium channel blockers (like carbamazepine or phenytoin) should generally be avoided because they can worsen seizures [7][8].
  • CDKL5 Deficiency Disorder (CDD):
    • Precision Med: Ganaxolone was specifically approved for CDD. It works by targeting the GABA-A receptors to quiet overactive brain signals [9][10].
  • SCN2A and SCN8A (Gain-of-Function):
    • Precision Med: If the mutation is a “Gain-of-Function” (the channel is “stuck on”), doctors often use high doses of Sodium Channel Blockers (SCBs) like phenytoin or carbamazepine to “plug” the overactive channel [11][12].
  • SLC2A1 (Glut1 Deficiency Syndrome):
    • Standard of Care: The Ketogenic Diet is the primary medical treatment. In this condition, the brain cannot get enough sugar (glucose) for fuel; the diet provides an alternative fuel source called “ketones” [13][14].

The Ketogenic Diet: A Medical Intervention

The Ketogenic Diet (KD) is not a lifestyle choice but a strictly controlled medical therapy [13]. It is high in fat and very low in carbohydrates, forcing the body to burn fat for energy [14].

  • When it is used: It is the “first-line” treatment for Glut1DS and is often highly effective for other DEEs like STXBP1 or refractory infantile spasms [13][15][16].
  • How it is managed: It must be started under the supervision of a specialized neurologist and a metabolic dietitian [17]. Regular blood tests are required to monitor “ketone levels” and ensure the child is getting proper nutrition [18].

The Future: Antisense Oligonucleotides (ASOs)

The next frontier in DEE treatment is Antisense Oligonucleotides (ASOs). These are short strands of synthetic genetic material designed to enter the cell and “fix” the way a gene is being read [19].

  • Upregulation: For conditions like Dravet (SCN1A), ASOs are being designed to tell the healthy copy of the gene to work “overtime” to make up for the mutated copy [19][20].
  • Downregulation: For Gain-of-Function mutations (like some SCN2A/SCN8A), ASOs can be used to “silence” the overactive mutated gene [21].
  • Status: While many ASOs are currently in clinical trials or preclinical research, they represent the ultimate goal of precision medicine: treating the genetic root rather than just the symptoms [22][23].
Treatment Type Examples Best For
GABA Modulators Fenfluramine, Stiripentol SCN1A (Dravet) [4][5].
Sodium Channel Blockers Carbamazepine, Phenytoin SCN2A/SCN8A Gain-of-Function [11][24].
Neuroactive Steroids Ganaxolone CDKL5 Deficiency [9].
Metabolic Therapy Ketogenic Diet Glut1DS, STXBP1, and drug-resistant epilepsy [13][15].

Always consult with a pediatric epilepsy specialist before making any changes to your child’s medication or diet, as these treatments require careful monitoring [18][8].

Return to Home Page

Common questions in this guide

What is precision medicine for Developmental and Epileptic Encephalopathy?
Precision medicine for DEE means doctors choose a treatment that specifically targets the underlying genetic mutation causing the seizures, rather than just using general anti-seizure medications. The goal is to improve both seizure control and developmental outcomes.
Why do we need to avoid certain medications in Dravet Syndrome?
In Dravet Syndrome, standard sodium channel blockers like carbamazepine or phenytoin should generally be avoided. Because Dravet is a loss-of-function condition, these particular medications can actually make seizures worse.
Is the ketogenic diet a proven treatment for DEE?
Yes, the medical ketogenic diet is a highly effective, strictly controlled medical therapy. It is the first-line standard of care for Glut1 Deficiency Syndrome and is also effective for other DEEs, providing an alternative fuel source for the brain.
What are Antisense Oligonucleotides (ASOs) for epilepsy?
ASOs are short strands of synthetic genetic material designed to correct how a specific gene is read by the body's cells. They are currently in clinical trials as a potential way to treat the genetic root cause of DEE instead of just managing symptoms.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my child's specific mutation, are they a candidate for precision medicines like Fenfluramine (for Dravet) or Ganaxolone (for CDKL5)?
  2. 2.If my child has an SCN2A or SCN8A mutation, have we confirmed it is 'Gain-of-Function' before using high-dose sodium channel blockers?
  3. 3.Is the Ketogenic Diet a first-line treatment for our specific genetic diagnosis, and how do we connect with a specialized metabolic dietitian?
  4. 4.Are there any medications my child is currently taking that are contraindicated for their specific gene (for example, avoiding sodium channel blockers in Dravet Syndrome)?
  5. 5.Are there any active clinical trials for Antisense Oligonucleotides (ASOs) or other gene-based therapies for this gene?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Targeted gene panel sequencing in early infantile onset developmental and epileptic encephalopathy.

    Na JH, Shin S, Yang D, et al.

    Brain & development 2020; (42(6)):438-448 doi:10.1016/j.braindev.2020.02.004.

    PMID: 32139178
  2. 2

    Nonseizure symptoms and broader seizure impacts in patients with Dravet syndrome and Lennox-Gastaut syndrome in clinical practice settings: Results from a multinational survey.

    Shah D, Villanueva V, Dlugos D, et al.

    Epilepsia open 2025; (10(6)):1783-1797 doi:10.1002/epi4.70118.

    PMID: 40982357
  3. 3

    Dravet Syndrome: An Overview.

    Anwar A, Saleem S, Patel UK, et al.

    Cureus 2019; (11(6)):e5006 doi:10.7759/cureus.5006.

    PMID: 31497436
  4. 4

    Efficacy and safety of fenfluramine in patients with Dravet syndrome: A meta-analysis.

    Zhang L, Li W, Wang C

    Acta neurologica Scandinavica 2021; (143(4)):339-348 doi:10.1111/ane.13387.

    PMID: 33336426
  5. 5

    Stiripentol: A Novel Antiseizure Medication for the Management of Dravet Syndrome.

    Buck ML, Goodkin HP

    The Annals of pharmacotherapy 2019; (53(11)):1136-1144 doi:10.1177/1060028019856008.

    PMID: 31167540
  6. 6

    Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.

    Devinsky O, Cross JH, Laux L, et al.

    The New England journal of medicine 2017; (376(21)):2011-2020 doi:10.1056/NEJMoa1611618.

    PMID: 28538134
  7. 7

    SCN1A/NaV 1.1 channelopathies: Mechanisms in expression systems, animal models, and human iPSC models.

    Mantegazza M, Broccoli V

    Epilepsia 2019; (60 Suppl 3()):S25-S38 doi:10.1111/epi.14700.

    PMID: 31904127
  8. 8

    Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice.

    Wirrell EC, Lagae L, Scheffer IE, et al.

    Epilepsia open 2024; (9(5)):1643-1657 doi:10.1002/epi4.12998.

    PMID: 38962968
  9. 9

    Ganaxolone: First Approval.

    Lamb YN

    Drugs 2022; (82(8)):933-940 doi:10.1007/s40265-022-01724-0.

    PMID: 35596878
  10. 10

    Ganaxolone: First FDA-approved Medicine for the Treatment of Seizures Associated with Cyclin-dependent Kinase-like 5 Deficiency Disorder.

    De SK

    Current medicinal chemistry 2024; (31(4)):388-392 doi:10.2174/0929867330666230320123952.

    PMID: 36959132
  11. 11

    Efficacy of sodium channel blockers in SCN2A early infantile epileptic encephalopathy.

    Dilena R, Striano P, Gennaro E, et al.

    Brain & development 2017; (39(4)):345-348 doi:10.1016/j.braindev.2016.10.015.

    PMID: 27876397
  12. 12

    SCN8A Encephalopathy: Case Report and Literature Review.

    Fan HC, Lee HF, Chi CS

    Neurology international 2021; (13(2)):143-150 doi:10.3390/neurolint13020014.

    PMID: 33915942
  13. 13

    Ketogenic diet therapy in children with epilepsy caused by SLC2A1 mutations: a single-center single-arm retrospective study.

    Wang YY, Zhou YQ, Luo LJ, et al.

    World journal of pediatrics : WJP 2024; (20(5)):517-524 doi:10.1007/s12519-022-00620-7.

    PMID: 36303089
  14. 14

    Food and Food Products on the Italian Market for Ketogenic Dietary Treatment of Neurological Diseases.

    Leone A, De Amicis R, Lessa C, et al.

    Nutrients 2019; (11(5)) doi:10.3390/nu11051104.

    PMID: 31108981
  15. 15

    A novel mutation in the DYNC1H1 gene causing developmental and epileptic encephalopathy treated with ketogenic diet: A case report.

    Zhao F, Sun L, Hu W, Zhang H

    Medicine 2025; (104(28)):e43277 doi:10.1097/MD.0000000000043277.

    PMID: 40660528
  16. 16

    Add-on ketogenic diet versus antiseizure medications alone in children with developmental and epileptic encephalopathies: a prospective comparative cohort study.

    Hu W, Li L, Zhao F, et al.

    Frontiers in neurology 2025; (16()):1677046 doi:10.3389/fneur.2025.1677046.

    PMID: 41127284
  17. 17

    GLUT1 deficiency syndrome in adulthood: lost in diagnosis.

    Previtali R, Adami L, Benvenuto C, et al.

    BMJ neurology open 2026; (8(1)):e001337 doi:10.1136/bmjno-2025-001337.

    PMID: 41561681
  18. 18

    Use of Remote Monitoring by E-mail for Long-Term Management of the Classic Ketogenic Diet.

    Ferraris C, Guglielmetti M, Tamagni E, et al.

    Nutrients 2020; (12(6)) doi:10.3390/nu12061833.

    PMID: 32575586
  19. 19

    Antisense oligonucleotides restore excitability, GABA signalling and sodium current density in a Dravet syndrome model.

    Yuan Y, Lopez-Santiago L, Denomme N, et al.

    Brain : a journal of neurology 2024; (147(4)):1231-1246 doi:10.1093/brain/awad349.

    PMID: 37812817
  20. 20

    Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome.

    Han Z, Chen C, Christiansen A, et al.

    Science translational medicine 2020; (12(558)) doi:10.1126/scitranslmed.aaz6100.

    PMID: 32848094
  21. 21

    Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gain-of-function epilepsy model.

    Li M, Jancovski N, Jafar-Nejad P, et al.

    The Journal of clinical investigation 2021; (131(23)).

    PMID: 34850743
  22. 22

    Comprehensive genetic diagnosis and therapeutic perspectives in 155 children with developmental and epileptic encephalopathy.

    van Heurck R, Hammar EB, Ville D, et al.

    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2025; (56()):97-103 doi:10.1016/j.ejpn.2025.04.014.

    PMID: 40347601
  23. 23

    Pharmacotherapeutic strategies for drug-resistant epilepsy in children.

    Auvin S, Specchio N

    Epilepsy & behavior : E&B 2024; (161()):110139 doi:10.1016/j.yebeh.2024.110139.

    PMID: 39515006
  24. 24

    Clinical study of 19 patients with SCN8A-related epilepsy: Two modes of onset regarding EEG and seizures.

    Denis J, Villeneuve N, Cacciagli P, et al.

    Epilepsia 2019; (60(5)):845-856 doi:10.1111/epi.14727.

    PMID: 31026061

This page is for educational purposes only and does not replace professional medical advice. Always consult a pediatric epilepsy specialist before making any changes to your child's medication or diet.

Get notified when new evidence is published on Genetic developmental and epileptic encephalopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.